A tumor test that will identify more patients who may preferentially benefit from PARP inhibitors than other biomarker assays1-5

Sources:

  1. Mirza et al. N Engl J Med (2016). 375:2154-2164.
  2. Ledermann et al. Lancet Oncol. (2014). 15:852-61.
  3. Kristeleit et al. Presented at European Cancer Congress 2016 (Abstract 8560).
  4. Dougherty et al. (Oncotarget 2017 8(27):43653-43661).
  5. Lheureux et al. J Clin Oncol (2015). 33 (suppl;abstr 5566).
  6. Abkevich et al. Br J Cancer (2012) 107:1776-1782.
  7. Popova et al. Cancer Res (2012) 72(21):5454-62.
  8. Birkback et al. Cancer Discov (2012) 2(4):366-75.
  9. Yates et al. Annals of Oncology (2014) 25 (suppl_4): iv305-iv326.
  10. The Cancer Genome Atlas. Nature (2011) 474:609-615.
  11. Timms et al. Br Ca Res (2014) 16:475-483.
  12. Telli et al. Clin Cancer Res (2016). In Press.
  13. Mills et al. Presented at 2016 SGO Annual Meeting on Women’s Cancer (abstract 2).
  14. Norquist et al. Presented at 2016 SGO Annual Meeting on Women’s Cancer (abstract 1).